AngioLab Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
16
- Stock Symbol
-
251280
- Share Price
-
$1.64
- (As of Thursday Closing)
AngioLab General Information
Description
AngioLab Inc is a biotechnology company. It is developing pharmaceuticals and health functional foods based on the inhibition of angiogenesis. The group is developing natural products and antibody-based pharmaceuticals.
Contact Information
Website
www.angiolab.co.krCorporate Office
- 65, Techno 3-ro
- Number 159, Gwanpyeong-dong, Hanshin S&M
- Daejeon, Yuseong 305-509
- South Korea
Corporate Office
- 65, Techno 3-ro
- Number 159, Gwanpyeong-dong, Hanshin S&M
- Daejeon, Yuseong 305-509
- South Korea
AngioLab Stock Performance
As of 19-Nov-2026, AngioLab’s stock price is $1.64. Its current market cap is $5.12M.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.64 | $1.57 | $1.01 - $2.86 | $5.12M | 1.45K | -$0.14 |
AngioLab Financials Summary
As of 31-Dec-2025, AngioLab has a trailing 12-month revenue of $1.59M.
|
In Thousands, USD |
TTM 31-Dec-2025 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 4,851 | 4,851 | 13,691 | 13,843 |
| Revenue | 1,591 | 1,591 | 1,498 | 380 |
| EBITDA | (352) | (352) | (553) | (1,765) |
| Net Income | (390) | (390) | (582) | (1,775) |
| Total Assets | 1,874 | 1,874 | 1,548 | 3,041 |
| Total Debt | 15 | 15 | 57 | 81 |
AngioLab Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AngioLab Patents
AngioLab Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022340371-A1 | Composition comprising horse chestnut extract | Pending | 01-Sep-2021 | ||
| CA-3226434-A1 | Composition comprising horse chestnut extract | Pending | 01-Sep-2021 | ||
| EP-4395802-A1 | Composition comprising horse chestnut extract | Pending | 01-Sep-2021 | ||
| EP-4395802-A4 | Composition comprising horse chestnut extract | Pending | 01-Sep-2021 | ||
| US-20240325484-A1 | Composition comprising horse chestnut extract | Pending | 01-Sep-2021 | A61K36/77 |
AngioLab Signals
AngioLab Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
AngioLab ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
AngioLab FAQs
-
When was AngioLab founded?
AngioLab was founded in 1999.
-
Where is AngioLab headquartered?
AngioLab is headquartered in Daejeon, South Korea.
-
What is the size of AngioLab?
AngioLab has 16 total employees.
-
What industry is AngioLab in?
AngioLab’s primary industry is Drug Discovery.
-
Is AngioLab a private or public company?
AngioLab is a Public company.
-
What is AngioLab’s stock symbol?
The ticker symbol for AngioLab is 251280.
-
What is the current stock price of AngioLab?
As of 19-Nov-2026 the stock price of AngioLab is $1.64.
-
What is the current market cap of AngioLab?
The current market capitalization of AngioLab is $5.12M.
-
What is AngioLab’s current revenue?
The trailing twelve month revenue for AngioLab is $1.59M.
-
What is AngioLab’s annual earnings per share (EPS)?
AngioLab’s EPS for 12 months was -$0.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process